Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.
Experts discuss evolving strategies in ER+/HER2- metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.
NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent. | May 24, 2023
(1)
GE Healthcare to scale Zionexa s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) posit
GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18),
used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare’s commitment to its precision health vision
and builds additional pipeline of oncology and neurology tracers to
help physicians personalize treatment
6 May
2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrog